Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I just picked up 2000 more at 16.08
Going back to 17 very soon
What a wonderful trading stock.
I sold early in the 17's. bought all my shares back sub-16
Then sold half of them again at 16.40
Wow. What a ride!
It will be moving up further next week!
The good news is "they" burned close to 90,000 shares EOD painting it to 2.41.
Eventually, the true value of this stock will come into play.
It is so heavily shorted, that once it starts to run and the covering starts, it should go like a runaway train!
Like a bad addiction, I keep buying more on these major dips.
I promised myself that I would stop acquiring shares when I got to 100,000 but I just cannot keep from accumulating more when I know the true value of these shares.
Lymphoseek will be huge once it gets in the hands of the radiologists!
MD Anderson understands the benefits and other folks will quickly follow suit.
If I don't stop buying soon, I may have to start the charter chapter of NAVBolics Anonymous!
Another crazy close. This time someone painted it red, red!
It's like the manipulators were playing the "two can play that game" theme.
This is just so nuts.
I seriously hope it sparks some interest with an investigator at the SEC.
I finally bailed at 9.16
Absorbed a $2500 hit. It just wasn't worth another week in the red to me.
I put this money to work in CZR and promptly made $180 back!
I will keep it on my watch list for now.
Welcome back.
It's good to have you back with us.
Do you think it could have been some shorts covering EOD?
Great close!!
I heard him saying that.
I picked some up per-market at $3.03
I'm happy with my trade and I agree that the long-term plan will be for on line gambling through state-approved venues.
This will be huge!
Still holding all of my shares.
We should be fine by next Spring.
I agree and ultimately will show financial security.
We will climb soon enough with revenue and added indications.
This will be $5 soon enough!
I picked up some more on the dip this AM!
Heading back over $17 soon!
Great past two days.
I'm staying in until $24's
Buying more on any significant dips!
I sold my shares this morning on the run up in 16.80's
And bought them all back later at 15.25
What an awesome trading stock!
Great day here!
Yes, it will go to 8.50 by eow.
Should get to $7.80's today
I did get some at 12.05
I may pick some more up today, but I also bought LVS
We shall see.
Thankfully, I've done we'll on my flips.
I bought more today at 2.44 and 2.42.
At this rate I will be on their board before much longer lol!
It just seems too good to pass up.
I know that Lymphoseek will take over this market once it is available in the radiology dept.
I trimmed a little today.
Holding the rest long term
I agree, this is fairly obvious manipulation.
I am here for the long run but it still looks pretty fishy to me!
I agree.
Thanks for the heads up a few days ago.
Looking to get back in this coming week.
Almost pulled the trigger today in the low 12's
Should move up after earnings season ends.
It's a great buying opportunity.
Time to load up.
This is going no where but up from these levels!
I was in here last summer and took a beating, but I have it on my watch list again for this coming week.
I'm still in here from 23.49
We shall see, but it continues to creep up daily despite the rest of the market.
It's been good to me so far!
Still in the red here from entry at 9.97.
Will watch closely next week. It's due for a break out!
I got out at $4.02 a few days ago, but I'm looking for a good re-entry point. Perhaps early next week?
It's going to be a great summer.
I don't see how we can go wrong with the terrific proposed dividends and a lot of upside room in the PPS over the next two quarters.
I will continue to accumulate on any dips!
Somebody painted it red right near the close today.
It just illustrates the short manipulation going on here.
Great news out but "they" are trying very hard to keep the PPS down.
It just seems like swimming against a strong current.
Sooner or later the current wins!
Navidea Biopharmaceuticals Announces that Results of NAV4694 Clinical Trial Published in the Journal of Nuclear Medicine
BusinessWire
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced the peer-reviewed publication of results from a clinical trial of NAV4694 in healthy subjects and those with diagnosed forms of dementia. The trial assessed the performance of Navidea's Fluorine-18 labeled amyloid imaging candidate, NAV4694, in a head-to-head comparison with the acknowledged benchmark, gold-standard amyloid imaging agent, (11)C-labeled Pittsburgh Compound-B(PiB). Results demonstrated that NAV4694 displayed imaging characteristics nearly identical to those of PiB and the authors believe these results show that NAV4694 may be useful in the early and differential diagnosis of Alzheimer's disease (AD). The study, "Head-to-Head Comparison of (11)C-PiB and (18)F-AZD4694 (NAV4694) for B-Amyloid Imaging in Aging and Dementia," was published in the current online edition of the Journal of Nuclear Medicine and will appear in the June print edition [J Nucl Med 2013; 54:1-7 DOI: 10.2967/jnumed.112.114785].
B-Amyloid imaging has the potential to play an increasingly important role in clinical practice as revised criteria for the diagnosis of probable AD allow for earlier diagnosis and therapeutic intervention. "For this to be a reality, clinicians will need access to reliable, practical and affordable imaging options," said Professor Christopher Rowe, MD, FRACP, Director of the Department of Nuclear Medicine and Centre for PET at Austin Health, Melbourne, Australia and one of the authors. "This study suggests that NAV4694 images may be more easily and reliably read in clinical practice than other F-18 labeled PET tracers. By displaying imaging characteristics nearly identical to those of the gold standard, PiB, NAV4694 provides the same low background needed for earlier differential diagnosis while affording the practicality needed for production logistics."
"With the ongoing movement toward earlier evaluation and treatment of cognitive impairment, it is of increasing importance for an improved diagnostic tool that can identify clinical dementia and cognitive impairment before it has fully developed," commented Cornelia Reininger, MD, PhD, Navidea's Senior Vice President and Chief Medical Officer. "These results add to our conviction that NAV4694, with its outstanding performance characteristics, may afford new opportunities to advance the early diagnosis of cognitive decline. We are very excited about the recent initiation of our Phase 2b study evaluating NAV4694 in the differentiation of Mild Cognitively Impaired (MCI) subjects who are at risk of developing Alzheimer's disease from those who are not, enabling the potential for early intervention with current and future treatments."
About the NAV4694 Head-to-Head Comparison Clinical Trial and Results
Forty-five participants (25 healthy elderly controls (HC), 10 with Mild Cognitive Impairment (MCI), 7 with AD and 3 with fronto-temporal dementia) underwent PET imaging with both PiB and NAV4694 imaging agents. The PiB and NAV4694 images were virtually indistinguishable by visual inspection and similarly low to no white matter binding was observed with both radiotracers. Low white matter binding coupled with comparatively high binding to target amyloid provide enhanced signal-to-noise ratios, facilitating detection of lower levels of amyloid. This may enable earlier detection of amyloid and therefore earlier diagnosis of the underlying cause of cognitive impairment and dementia. When quantified, there were no significant differences in white matter binding for each tracer in both healthy controls and dementia subjects. The quantitative measures of NAV4694 binding to cortical amyloid plaques showed almost identical results to PIB. There was an excellent linear correlation between PiB and NAV4694 neocortical standardized uptake value ratios, or SUVR, (slope of 0.95, r = 0.99, P < 0.0001). Both radiotracers showed similar binding kinetics and dynamic range. As expected, the AD group showed higher B-Amyloid detection than the HCs, as measured by both PiB and NAV4694 binding, and provided a robust separation of AD patients from HCs. Of note, the authors state that visually, 16% of the Healthy Controls were deemed positive for B-Amyloid as assessed by both PiB and NAV4694, presenting an almost identical pattern of binding suggesting that B-Amyloid deposition is an early feature of the disease preceding cognitive impairment. No serious adverse events related to the study drugs were observed or reported by any participants as a result of the PiB or NAV4694 scans, and no concerns were raised by the participants or their relatives.
About NAV4694
NAV4694 is a Fluorine-18 labeled precision radiopharmaceutical candidate intended for use in Positron Emission Tomography (PET) imaging and evaluation of patients with signs or symptoms of cognitive impairment such as Alzheimer's disease (AD). NAV4694 binds to B-Amyloid deposits in the brain that can then be imaged in scans. B-Amyloid plaque pathology is widely used in the diagnosis of AD. The ability of NAV4694 imaging to display amyloid plaque pathology may enable earlier identification of AD and improve monitoring of disease progression and interpretation of brain scan images. Navidea plans for a Phase 3 trial of NAV4694 to begin in 2013.
About Alzheimer's
Alzheimer's disease (AD) is a progressive and fatal neurodegenerative disease which affects a person's memory and ability to learn, reason, communicate and carry out daily activities. Increasing age is the greatest risk factor for AD and there is no prevention or cure. The World Health Organization estimates that Alzheimer's disease affects over 24,000,000 people worldwide. Currently in the U.S. alone, there are over 5 million Alzheimer's patients with estimates that by 2050, as many as 14 million Americans could have the disease according to the Alzheimer's Association. Among the brain changes believed to contribute to the development of Alzheimer's are the accumulation of the protein B-Amyloid outside nerve cells (neurons) in the brain and the accumulation of the protein tau inside neurons. Approximately 75 to 100 experimental pharmaceuticals aimed at diagnosing, slowing or stopping the progression of Alzheimer's are now in human clinical trials.
About Navidea Biopharmaceuticals, Inc.
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) is a biopharmaceutical company focused on the development and commercialization of precision diagnostics and radiopharmaceutical agents. Navidea is actively developing four radiopharmaceutical agent platforms - Lymphoseek(R), NAV4694, NAV5001 and RIGScan(TM) - to help identify the sites and pathways of undetected disease and enable better diagnostic accuracy, clinical decision-making and, ultimately, patient care. Navidea's strategy is to deliver superior growth and shareholder return by bringing to market novel radiopharmaceutical agents and advancing the Company's pipeline through selective acquisitions, global partnering and commercialization efforts. For more information, please visit www.navidea.com.
The Private Securities Litigation Reform Act of 1995 (the Act) provides a safe harbor for forward-looking statements made by or on behalf of the Company. Statements in this news release, which relate to other than strictly historical facts, such as statements about the Company's plans and strategies, expectations for future financial performance, new and existing products and technologies, anticipated clinical and regulatory pathways, and markets for the Company's products are forward-looking statements within the meaning of the Act. The words "believe," "expect," "anticipate," "estimate," "project," and similar expressions identify forward-looking statements that speak only as of the date hereof. Investors are cautioned that such statements involve risks and uncertainties that could cause actual results to differ materially from historical or anticipated results due to many factors, including, but not limited to, the Company's continuing operating losses, uncertainty of market acceptance of its products, reliance on third-party manufacturers, accumulated deficit, future capital needs, uncertainty of capital funding, dependence on limited product line and distribution channels, competition, limited marketing and manufacturing experience, risks of development of new products, regulatory risks and other risks detailed in the Company's most recent Annual Report on Form 10-K and other Securities and Exchange Commission filings. The Company undertakes no obligation to publicly update or revise any forward-looking statements.
http://cts.businesswire.com/ct/CT?id=bwnews&sty=20130418006319r1&sid=cmtx4&distro=nx
SOURCE: Navidea Biopharmaceuticals, Inc.
Investors:
Navidea Biopharmaceuticals, Inc.
Brent Larson, Sr. VP & CFO
614-822-2330
http://cts.businesswire.com/ct/CT?id=bwnews&sty=20130418006319r1&sid=cmtx4&distro=nx
This is big.
Hopefully, we should see the PPS pop a bit tomorrow.
I agree.
I have a very large position here, and I am holding long.
I see this easily over $5 within 12 months.
Yes. That's what I meant.
It's just incredible that we got approval and the share price fell.
I'm in for the long haul on this one!
I'm in here at $6.89
Looking for it to continue its climb
Agree 100%
Nothing more than overreaction
Great buying opportunity
I think you made a great move.
I have had it since my entry at $15.43
This S&P is headed for 1700 and XIV will enjoy a nice ride up this next 2 Q's
The catalysts came and went. It was approved by the FDA, but the short interest has kept it down artificially.
The news keeps coming out positive. We are probably having to wait on revenues.
The good news is that they have a great product and pipeline and a great partner in Cardinal Health to get Lymphoseek in front of the prescribers.
It was a great close.
I thought perhaps some of the shorts were covering but the blocks were small.
The true price of this stock should be around $3.50 with easy potential to get over $6 with a well defined book of business.
Perhaps folks are just finally starting to realize the true value here?
Whatever the reason, I expect the short interest to be back at it tomorrow, but I have to believe that a better play now would be to cover and flip to a long position?